Adrian Kinkaid
Directeur Général chez FUSION ANTIBODIES PLC
Fortune : 22 058 $ au 30/04/2024
Profil
Adrian Kinkaid is currently the Chief Executive Officer & Director at Fusion Antibodies Plc since 2022.
Prior to this, he was the Chief Executive Officer at MIP Discovery Ltd.
(United Kingdom) from 2015 to 2022.
Dr. Kinkaid holds a doctorate degree from The University of Southampton.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
FUSION ANTIBODIES PLC
0,57% | 14/02/2024 | 546 272 ( 0,57% ) | 22 058 $ | 30/04/2024 |
Postes actifs de Adrian Kinkaid
| Sociétés | Poste | Début |
|---|---|---|
| FUSION ANTIBODIES PLC | Directeur Général | 15/08/2022 |
Anciens postes connus de Adrian Kinkaid
| Sociétés | Poste | Fin |
|---|---|---|
MIP Discovery Ltd. (United Kingdom)
 MIP Discovery Ltd. (United Kingdom) Miscellaneous Commercial ServicesCommercial Services MIP Diagnostic Ltd. develops molecularly imprinted polymers for research purposes, diagnostics and drugs. The company was founded by Sergey Piletsky in 2015 and is headquartered in Leicester, the United Kingdom. | Directeur Général | 15/08/2022 |
Formation de Adrian Kinkaid
| The University of Southampton | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| FUSION ANTIBODIES PLC | Health Services |
| Entreprise privées | 1 |
|---|---|
MIP Discovery Ltd. (United Kingdom)
MIP Discovery Ltd. (United Kingdom) Miscellaneous Commercial ServicesCommercial Services MIP Diagnostic Ltd. develops molecularly imprinted polymers for research purposes, diagnostics and drugs. The company was founded by Sergey Piletsky in 2015 and is headquartered in Leicester, the United Kingdom. | Commercial Services |
